{
  "abstract": "Background. Despite decades of EEG biomarker development for amyotrophic lateral sclerosis (ALS), no candidate has progressed to clinical deployment, partly because cross-cohort validation is rare. We aimed to develop and demonstrate a pre-registered three-criterion screening framework to identify which candidate EEG features show the combined properties required for biomarker translation: cross-sectional discrimination, within-subject reliability, and cross-cohort effect consistency. Methods. We pre-registered a validation framework adapted from FDA-NIH BEST principles and applied it to 18 EEG features across three independent cohorts: EEGET-ALS (six ALS patients, 170 healthy controls; home recordings over 17 days), UCL/Penn State (eight ALS patients; clinic recordings over 1-2 months), and a healthy adult test-retest reference (60 participants, three sessions over one month). Features were required to meet three pre-registered criteria: (1) cross-sectional discrimination (Cohen's d > 0.5), (2) within-subject reliability (ICC(3,1) > 0.6 in both ALS cohorts independently), and (3) cross-cohort effect direction consistency. Cross-cohort permutation testing (1000 iterations) and subject-level bootstrap resampling (500 iterations) were applied to assess robustness. Results. Three features met all three pre-registered criteria: gamma power, theta power, and spectral entropy. Cross-cohort permutation testing showed that no permutation, out of 1000, produced any feature in the three-cohort reliability intersection (Monte Carlo p = 0.001). Bootstrap resampling indicated that the composition of the selected set was sensitive to sample composition (median count 1, 95% CI [0, 4]), with gamma power (67% inclusion), spectral entropy (43%), and theta power (32%) the most stable features at a relaxed reliability threshold (ICC > 0.5); at the primary pre-registered threshold (ICC > 0.6), the corresponding inclusion probabilities are lower (57%, 27%, and 19%, respectively). A principal methodological finding was that cross-cohort differences in feature reliability were large relative to the apparent disease-associated signal, most clearly demonstrated by relative beta power (ICC = 0.09 in a home-recorded cohort versus 0.93 in a clinic-recorded cohort); because recording protocol, hardware, setting, population, and preprocessing all differ jointly between cohorts in this dataset, this is evidence of cohort-associated variability that plausibly includes a protocol contribution, not a separately identified, isolated protocol effect. Conclusions. This study provides a pre-registered, multi-cohort EEG biomarker screening framework for ALS with explicit bootstrap-quantified uncertainty. Gamma power, spectral entropy, and theta power are identified as priority candidates for prospective validation. A recurring methodological observation is that protocol-related cohort differences appear to contribute more to cross-cohort variability than disease-related effects within this dataset; because protocol is confounded with cohort, equipment, and preprocessing, this pattern is descriptive rather than causal. The observation nonetheless has direct implications for the design of multi-site EEG biomarker studies in neural engineering.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Pharmacy, College of Health Sciences and Comprehensive Specialized Hospital, Axum University, Axum, Ethiopia"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "name": "B. T. Gebregergis"
    },
    {
      "name": "H. G. Yhdego"
    },
    {
      "affs": [
        0
      ],
      "name": "T. Teklu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8cck4eghreg2g.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.11.10.26367741",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367741v1.full",
  "id": "8cck4eghreg2g",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367741v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "neurology"
    ]
  ],
  "openalex": null,
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367741v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-10",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8cck4eghreg2g.ris",
  "sources": [
    {
      "first_seen": "2026-11-13T00:21:32Z",
      "native_id": "10.64898/2026.11.10.26367741",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367741v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:neurology",
      "subfield": "neurology"
    }
  ],
  "title": "Cross-cohort validation of EEG biomarkers using a pre-registered three-criterion framework: a demonstration in amyotrophic lateral sclerosis",
  "title_text": "Cross-cohort validation of EEG biomarkers using a pre-registered three-criterion framework: a demonstration in amyotrophic lateral sclerosis",
  "type": "preprint",
  "updated_at": "2026-11-14T00:20:23Z",
  "url": "https://research.draconitic.com/paper/8cck4eghreg2g",
  "venue": "medRxiv",
  "versions": []
}